We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reneuron Group Plc | LSE:RENE | London | Ordinary Share | GB00BF5G6K95 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.05 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 530k | -5.41M | -0.0946 | -0.32 | 1.74M |
Date | Subject | Author | Discuss |
---|---|---|---|
27/3/2014 07:52 | This time next year Rodders... | jwoolley | |
27/3/2014 07:25 | Well that didnt take long .................... feels like a life time ago when i bought these bloody things | sitiain | |
21/3/2014 19:31 | for p2 001, first they need to recruit then they have to carry out two years of trials then a six month follow up then you will get some price sensitive news. trouble is that's three years away and the share price is likely to be wallowing at around half a penny by then, that's if they've not gone into admin before! | rocket fuel | |
18/3/2014 11:54 | When do we expect any further news on the clinical trials? | stewart_25 | |
17/3/2014 08:54 | Hyper, yes (and at a higher share price than today) but not in a big way. Don't tend to trade much, which I'm sure would have been more profitable. Next update from Glasgow should be interesting! | waterloo01 | |
17/3/2014 08:47 | waterloo01 Good morning. Have followed this one for what seems like decades and have done quite well on the occasional short term trade. Not in just now, are you? | hyper al | |
14/3/2014 09:07 | Two quick ones. Story about the easy way to produce stem cells (as published in Nature) is now being called into question. Telegraph today Who could benefit from the scheme? CTX Disease area: Recovery from strokes, which occur when the blood supply is cut off to part of the brain. Who's developing it? ReNeuron, an Aim-listed biotech company based in Guildford. What does it do? The specially developed stem cells, when injected into the brains of recovering stroke patients, are thought to stimulate the growth of new blood vessels and new nerves. Why is it promising? ReNeuron has completed early clinical trials in a small group of patients in Glasgow, showing that it is safe to use in humans. These trials were not designed to test the effectiveness of the drug but some of the patients involved have shown marked improvements. | waterloo01 | |
14/3/2014 08:12 | * PHARMACEUTICALS - Britain is to accelerate access to ground-breaking drugs for serious conditions under a new early-access plan that the government hopes will benefit both patients and pharmaceutical companies. | ps0u3165 | |
20/2/2014 13:38 | he says on a day when it drops back .21 lol. | stewart_25 | |
20/2/2014 13:14 | Well said ;) | 1titch | |
20/2/2014 12:39 | We're all here. We're waiting for the share price to breach 4p and we'll be able to post '4p breached'. In other words, there is no news flow to comment on. But when it comes...4p will be breached! | verger | |
18/2/2014 12:47 | several ups and downs and nothing from posters - has everyone left ADVFN? | stewart_25 | |
04/2/2014 11:33 | and back down.... | stewart_25 | |
03/2/2014 15:13 | best kept that way | bigspuds | |
03/2/2014 13:49 | With the rise today it's very quiet on here. | curlly | |
03/2/2014 13:27 | nice rises - can we sustain it? | stewart_25 | |
03/2/2014 11:04 | With the latest bbc report looks like we are starting to push north | curlly | |
31/1/2014 11:01 | thankx qpr - to what price? | stewart_25 | |
31/1/2014 09:58 | stewart 25 BUY | qpr67 | |
31/1/2014 09:56 | Can you link it goodbloke (not related to goodfella another old time poster are ya?) | marcus wanky | |
31/1/2014 09:54 | On LSE board fully pasted article | goodbloke45 | |
31/1/2014 09:53 | Look at LSE pasted on there | goodbloke45 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions